Effect of LCZ696 and Its Components Sacubitril and Valsartan on Insulin Secretion and Glucose Homeostasis in Mice

被引：0
|
作者：
Esser, Nathalie
Schmidt, Christine R.
Barrow, Breanne
Cronic, Laura
Hackney, Daryl J.
Mongovin, Steve M.
Hull, Rebecca L.
Zraika, Sakeneh
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-1797-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1797-P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Effects of LCZ696 (Sacubitril/Valsartan) on Blood Pressure in Patients with Hypertension: A Meta-Analysis of Randomized Controlled Trials
    Geng, Qiang
    Yan, Rongqiang
    Wang, Zhengzhong
    Hou, Fangjie
    CARDIOLOGY, 2020, 145 (09) : 589 - 598
  • [32] Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects
    Han, Yi
    Ayalasomayajula, Surya
    Pan, Wei
    Yang, Fan
    Yuan, Yaozong
    Langenickel, Thomas
    Hinder, Markus
    Kalluri, Sampath
    Pal, Parasar
    Sunkara, Gangadhar
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2017, 42 (01) : 109 - 116
  • [33] Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany
    Gandjour, Afschin
    Ostwald, Dennis A.
    PHARMACOECONOMICS, 2018, 36 (10) : 1285 - 1296
  • [34] Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany
    Afschin Gandjour
    Dennis A. Ostwald
    PharmacoEconomics, 2018, 36 : 1285 - 1296
  • [35] Disposition and metabolism of [14C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects
    Flarakos, Jimmy
    Du, Yancy
    Bedman, Timothy
    Al-Share, Qusai
    Jordaan, Pierre
    Chandra, Priya
    Albrecht, Diego
    Wang, Lai
    Gu, Helen
    Einolf, Heidi J.
    Huskey, Su-Er
    Mangold, James B.
    XENOBIOTICA, 2016, 46 (11) : 986 - 1000
  • [36] Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolledwith amlodipine monotherapy
    Wang, Ji-Guang
    Yukisada, Kimihiko
    Sibulo, Antonio, Jr.
    Hafeez, Kudsia
    Jia, Yan
    Zhang, Jack
    JOURNAL OF HYPERTENSION, 2017, 35 (04) : 877 - 885
  • [37] LCZ696 (sacubitril/valsartan) inhibits pulmonary hypertension induced right ventricular remodeling by targeting pyruvate dehydrogenase kinase 4
    Shen, Mengjia
    Zheng, Cankun
    Chen, Lu
    Li, Mingjue
    Huang, Xiaoxia
    He, Mingyuan
    Liu, Chiyu
    Lin, Hairuo
    Liao, Wangjun
    Bin, Jianping
    Cao, Shiping
    Liao, Yulin
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 162
  • [38] First derivative emission spectrofluorimetric method for the determination of LCZ696, a newly approved FDA supramolecular complex of valsartan and sacubitril in tablets
    Ragab, Marwa A. A.
    Galal, Shereen M.
    Korany, Mohamed A.
    Ahmed, Aya R.
    LUMINESCENCE, 2017, 32 (08) : 1417 - 1425
  • [39] Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension
    Wang, Tzung-Dau
    Tan, Ru-San
    Lee, Hae-Young
    Ihm, Sang-Hyun
    Rhee, Moo-Yong
    Tomlinson, Brian
    Pal, Parasar
    Yang, Fan
    Hirschhorn, Elizabeth
    Prescott, Margaret F.
    Hinder, Markus
    Langenickel, Thomas H.
    HYPERTENSION, 2017, 69 (01) : 32 - 41
  • [40] Prevention of Progressive Worsening of Heart Failure Over Time With The Angiotensin-receptor Neprilysin Inhibitor Sacubitril/valsartan (lcz696)
    McMurray, John
    Jhund, Pardeep
    Gong, Jianjian
    Rouleau, Jean
    Lefkowitz, Martin
    Desai, Akshay
    Rizkala, Adel
    Shi, Victor
    Swedberg, Karl
    Zile, Michael
    Solomon, Scott
    Packer, Milton
    CIRCULATION, 2015, 132
12345